100
Participants
Start Date
July 31, 2011
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2013
Brivaracetam
"Oral solution~Evaluation period (3 weeks up-titration):~For subjects ≥8 years:~* \~0.4 mg/kg bid for Week 1~* \~0.8 mg/kg bid for Week 2~* \~1.6 mg/kg bid for Week 3~For subjects \<8 years:~* \~0.5 mg/kg bid for Week 1~* \~1.0 mg/kg bid for Week 2~* \~2.0 mg/kg bid for Week 3~Down-titration period (up to 2 weeks):~For subjects ≥8 years:~* \~0.8 mg/kg bid for Week 4~* \~0.4 mg/kg bid for Week 5~For subjects \<8 years:~* \~1.0 mg/kg bid for Week 4~* \~0.5 mg/kg bid for Week 5"
108, Gulf Breeze
110, Miami
103, Wellington
106, Boston
101, Saint Paul
113, Chesterfield
105, Buffalo
104, Rochester
107, Cincinnati
114, Pittsburgh
109, Nashville
117, Houston
202, Brussels
203, Brussels
201, Leuven
502, Hradec Králové
504, Ostrava Porubo
501, Prague
602, Aguascalientes
611, Chihuahua City
609, Ciuliacan
603, Guadalajara
604, Mexico City
610, Monterrey
607, San Luis Potosí City
404, Bialystok
403, Gdansk
406, Kielce
402, Krakow
401, Poznan
408, Rzeszów
407, Szczecin
405, Wroclaw
309, Barcelona
306, Madrid
301, Palma de Mallorca
304, Santander
308, Valencia
303, Zaragoza
Lead Sponsor
UCB Pharma
INDUSTRY